{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:24:01Z","timestamp":1785900241757,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006196","name":"University of Oulu","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006196","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Although the increasing use of PET-CT has enabled improvements in staging and confirmation of a suspected histological transformation of follicular lymphoma (FL), the disease is still characterised by varied courses and outcomes. Our aim was to determine, whether diagnostic PET-CT could be effective in preventing early progression, particularly disease progression within 24 months of started therapy (POD24). Patient data of 177 grade 1-3a FL patients treated in Oulu University Hospital between years 2000 and 2020 was retrospectively reviewed. Staging of 59 patients included PET-CT before first-line treatment, when excluding two patients who were found to be primary transformed based on their PET-CT. 25 (42.4%) of the 59 patients were also re-biopsied based on the staging results. The control group consisted of 118 non-PET-CT staged patients who received systemic therapy for their disease. The use of PET-CT at the time of the diagnosis was determined by clinician based on the clinical course of the individual patient. In the PET-CT staged group four transformations were noted during follow-up and six cases of POD24 occurred. In comparison, fifteen transformations (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.306) and 18 POD24 (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.486) occurred in the reference group. A high SUVmax was indicative of worse outcomes (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.016) but survival was not improved in the re-biopsied subgroup. Diagnostic PET-CT enhanced disease course as time to progression was superior in the group of PET-CT staged patients (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.038). Our results suggest that PET-CT is a valuable diagnostic tool at baseline which may help to identify patients at risk for POD24 leading to better survival.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06609-2","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:28:04Z","timestamp":1759732084000},"page":"5297-5307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Patients with follicular lymphoma should be treated according to baseline PET-CT findings with targeted re-biopsy"],"prefix":"10.1007","volume":"104","author":[{"given":"Anni","family":"Nyyss\u00f6nen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Vuolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Vaattovaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aino","family":"Rajam\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taina","family":"Turpeenniemi-Hujanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Sorigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Kuitunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milla E.L.","family":"Kuusisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"6609_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/S41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/S41375-022-01620-2","journal-title":"Leukemia"},{"key":"6609_CR2","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. J Clin Oncol 33:2516\u20132522. https:\/\/doi.org\/10.1200\/JCO.2014.59.7534","journal-title":"J Clin Oncol"},{"key":"6609_CR3","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3324\/HAEMATOL.2018.209015","volume":"104","author":"JF Seymour","year":"2019","unstructured":"Seymour JF, Marcus R, Davies A et al (2019) Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica 104:1202\u20131208. https:\/\/doi.org\/10.3324\/HAEMATOL.2018.209015","journal-title":"Haematologica"},{"key":"6609_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/BLOOD.2020010263","volume":"139","author":"C Casulo","year":"2022","unstructured":"Casulo C, Dixon JG, Le-Rademacher J et al (2022) Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood 139:1684\u20131693. https:\/\/doi.org\/10.1182\/BLOOD.2020010263","journal-title":"Blood"},{"key":"6609_CR5","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/BLOOD.2019001091","volume":"135","author":"F Mir","year":"2020","unstructured":"Mir F, Barrington SF, Brown H et al (2020) Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood 135:1214\u20131218. https:\/\/doi.org\/10.1182\/BLOOD.2019001091","journal-title":"Blood"},{"key":"6609_CR6","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2967\/JNUMED.114.149625","volume":"56","author":"MJ Wondergem","year":"2015","unstructured":"Wondergem MJ, Rizvi SNF, Jauw Y et al (2015) 18F-FDG or 3\u2019-deoxy-3\u2019-18F-fluorothymidine to detect transformation of follicular lymphoma. J Nucl Med 56:216\u2013221. https:\/\/doi.org\/10.2967\/JNUMED.114.149625","journal-title":"J Nucl Med"},{"key":"6609_CR7","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1200\/JCO.2010.32.5225","volume":"29","author":"BD Cheson","year":"2011","unstructured":"Cheson BD (2011) Role of functional imaging in the management of lymphoma. J Clin Oncol 29:1844\u20131854. https:\/\/doi.org\/10.1200\/JCO.2010.32.5225","journal-title":"J Clin Oncol"},{"key":"6609_CR8","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"6609_CR9","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1093\/ANNONC\/MDP030","volume":"20","author":"JYY Ngeow","year":"2009","unstructured":"Ngeow JYY, Quek RHH, Ng DCE et al (2009) High SUV uptake on FDG-PET\/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET\/CT staging in lymphoma. Ann Oncol 20:1543\u20131547. https:\/\/doi.org\/10.1093\/ANNONC\/MDP030","journal-title":"Ann Oncol"},{"key":"6609_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/S00277-017-3151-2","volume":"97","author":"T Fischer","year":"2018","unstructured":"Fischer T, Zing NPC, Chiattone CS et al (2018) Transformed follicular lymphoma. Ann Hematol 97:17\u201329. https:\/\/doi.org\/10.1007\/S00277-017-3151-2","journal-title":"Ann Hematol"},{"key":"6609_CR11","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P et al (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol 37:2815\u20132824. https:\/\/doi.org\/10.1200\/JCO.19.01073","journal-title":"J Clin Oncol"},{"key":"6609_CR12","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy C, Maurer MJ, Link BK et al (2019) Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol 37:144\u2013152. https:\/\/doi.org\/10.1200\/JCO.18.00400","journal-title":"J Clin Oncol"},{"key":"6609_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/J.REMNIE.2022.03.002","volume":"41","author":"A D\u00edaz-Silv\u00e1n","year":"2022","unstructured":"D\u00edaz-Silv\u00e1n A, Ot\u00f3n-S\u00e1nchez LF, Caresia-Ar\u00f3ztegui AP et al (2022) Clinical application of [18F]FDG PET\/CT in follicular lymphoma. Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition) 41:202\u2013212. https:\/\/doi.org\/10.1016\/J.REMNIE.2022.03.002","journal-title":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"},{"key":"6609_CR14","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.7150\/JCA.87523","volume":"14","author":"Y Jing","year":"2023","unstructured":"Jing Y, Chen Y, Yu Y et al (2023) FDG-PET\/CT provides clues on bone marrow involvement in follicular lymphoma and carries important prognostic information. J Cancer 14:2726\u20132738. https:\/\/doi.org\/10.7150\/JCA.87523","journal-title":"J Cancer"},{"key":"6609_CR15","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1182\/BLOODADVANCES.2020001579","volume":"4","author":"R Nakajima","year":"2020","unstructured":"Nakajima R, Moskowitz AJ, Michaud L et al (2020) Baseline FDG-PET\/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. Blood Adv 4:1812\u20131823. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020001579","journal-title":"Blood Adv"},{"key":"6609_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/J.EJCA.2019.12.006","volume":"126","author":"CL Batlevi","year":"2020","unstructured":"Batlevi CL, Sha F, Alperovich A et al (2020) Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. Eur J Cancer 126:78\u201390. https:\/\/doi.org\/10.1016\/J.EJCA.2019.12.006","journal-title":"Eur J Cancer"},{"key":"6609_CR17","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/S00277-020-04025-2","volume":"99","author":"C Sortais","year":"2020","unstructured":"Sortais C, Lok A, Tessoulin B et al (2020) Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. Ann Hematol 99:1595\u20131604. https:\/\/doi.org\/10.1007\/S00277-020-04025-2","journal-title":"Ann Hematol"},{"key":"6609_CR18","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1200\/JCO.18.00262","volume":"36","author":"S Lockmer","year":"2018","unstructured":"Lockmer S, \u00d8stenstad B, Hagberg H et al (2018) Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two nordic lymphoma group trials with more than 10 years of follow-up. J Clin Oncol 36:3315\u20133323. https:\/\/doi.org\/10.1200\/JCO.18.00262","journal-title":"J Clin Oncol"},{"key":"6609_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/BLOOD.2019000258","volume":"134","author":"CL Freeman","year":"2019","unstructured":"Freeman CL, Kridel R, Moccia AA et al (2019) Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood 134:761\u2013764. https:\/\/doi.org\/10.1182\/BLOOD.2019000258","journal-title":"Blood"},{"key":"6609_CR20","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/S12185-022-03418-5","volume":"116","author":"W Kuroki","year":"2022","unstructured":"Kuroki W, Kitadate A, Ishiyama K et al (2022) High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma. Int J Hematol 116:712\u2013722. https:\/\/doi.org\/10.1007\/S12185-022-03418-5","journal-title":"Int J Hematol"},{"key":"6609_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/BLOOD-2014-04-516815","volume":"125","author":"C Casulo","year":"2015","unstructured":"Casulo C, Burack WR, Friedberg JW (2015) Transformed follicular non-Hodgkin lymphoma. Blood 125:40\u201347. https:\/\/doi.org\/10.1182\/BLOOD-2014-04-516815","journal-title":"Blood"},{"key":"6609_CR22","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/CAM4.4924","volume":"12","author":"A Rajam\u00e4ki","year":"2023","unstructured":"Rajam\u00e4ki A, Kuitunen H, Sorigue M et al (2023) FDG-PET\/CT-guided rebiopsy may find clinically unsuspicious transformation of follicular lymphoma. Cancer Med 12:407\u2013411. https:\/\/doi.org\/10.1002\/CAM4.4924","journal-title":"Cancer Med"},{"key":"6609_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3324\/HAEMATOL.2020.263194","volume":"107","author":"C Rossi","year":"2022","unstructured":"Rossi C, Tosolini M, Gravelle P et al (2022) Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica 107:221\u2013230. https:\/\/doi.org\/10.3324\/HAEMATOL.2020.263194","journal-title":"Haematologica"},{"key":"6609_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/ANNONC\/MDN657","volume":"20","author":"A Noy","year":"2009","unstructured":"Noy A, Sch\u00f6der H, G\u00f6nen M et al (2009) The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). Ann Oncol 20:508\u2013512. https:\/\/doi.org\/10.1093\/ANNONC\/MDN657","journal-title":"Ann Oncol"},{"key":"6609_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3324\/HAEMATOL.12013","volume":"93","author":"C Bodet-Milin","year":"2008","unstructured":"Bodet-Milin C, Kraeber-Bod\u00e9r\u00e9 F, Moreau P et al (2008) Investigation of FDG-PET\/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica 93:471\u2013472. https:\/\/doi.org\/10.3324\/HAEMATOL.12013","journal-title":"Haematologica"},{"issue":"3","key":"6609_CR26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/J.SEMNUCLMED.2022.11.001","volume":"53","author":"L Zanoni","year":"2023","unstructured":"Zanoni L, Bezzi D, Nanni C et al (2023) PET\/CT in Non-Hodgkin lymphoma: an update. Semin Nucl Med 53(3):320\u2013351. https:\/\/doi.org\/10.1053\/J.SEMNUCLMED.2022.11.001","journal-title":"Semin Nucl Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06609-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06609-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06609-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:18:58Z","timestamp":1763194738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06609-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6609"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06609-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed following the principles of Declaration of Helsinki and approved by the Ethics Committee of the Northern Ostrobothnia Hospital District, Oulu University Hospital. As the current study is a retrospective effort utilising register-based data used for clinical purposes the Finnish and EU legislation require no informed consent of patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}